Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease

dc.contributor.authorFarlow, Martin R.
dc.contributor.authorSadowsky, Carl H.
dc.contributor.authorVelting, Drew M.
dc.contributor.authorMeng, Xiangyi
dc.contributor.authorIslam, M. Zahur
dc.contributor.departmentNeurology, School of Medicineen_US
dc.date.accessioned2019-08-27T15:42:58Z
dc.date.available2019-08-27T15:42:58Z
dc.date.issued2015-06
dc.description.abstractAIMS: To identify factors predicting improvement/stabilization on the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC) and investigate whether early treatment responses can predict long-term outcomes, during a trial of 13.3 mg/24 h versus 4.6 mg/24 h rivastigmine patch in patients with severe Alzheimer's disease (AD). METHODS: Logistic regression was used to relate Week 24 ADCS-CGIC score to potential baseline predictors. Additional analyses based on receiver-operating characteristic curves were performed using Week 8/16 ADCS-CGIC scores to predict response (13.3 mg/24 h patch) at Week 24. ADCS-CGIC score of (1) 1-3 = "improvement," (2) 1-4 = "improvement or no change". RESULTS: "Treatment" (13.3 mg/24 h patch) and increased age were significant predictors of "improvement" (P = 0.01 and P = 0.003, respectively), and "treatment" (P = 0.001), increased age (P = 0.002), and prior AD treatment (P = 0.03) for "improvement or no change". At Week 8 and 16, ADCS-CGIC scores of 4 and 5 were optimal thresholds in predicting "improvement," and "improvement or no change," respectively, at Week 24. CONCLUSIONS: A significant therapeutic effect of high-dose rivastigmine patch on ADCS-CGIC response was observed. The 13.3 mg/24 h patch was identified as a predictor of "improvement" or "improvement or no change". Patients with minimal worsening/improvement/no change after treatment initiation may be more likely to respond following long-term therapy.en_US
dc.identifier.citationFarlow, M. R., Sadowsky, C. H., Velting, D. M., Meng, X., & Islam, M. Z. (2015). Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease. CNS neuroscience & therapeutics, 21(6), 513–519. doi:10.1111/cns.12385en_US
dc.identifier.urihttps://hdl.handle.net/1805/20606
dc.language.isoen_USen_US
dc.publisherWileyen_US
dc.relation.isversionof10.1111/cns.12385en_US
dc.relation.journalCNS Neuroscience & Therapeuticsen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/3.0/us*
dc.sourcePMCen_US
dc.subjectAlzheimer diseaseen_US
dc.subjectPredictoren_US
dc.subjectRivastigmineen_US
dc.subjectReceiver‐operating characteristicen_US
dc.subjectTransdermal patchen_US
dc.titleEvaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Diseaseen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
CNS-21-513.pdf
Size:
220.6 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: